Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Xinru Ren, X. Gregory Chen, William Wang & Yodit Seifu. (2023) Estimand in benefit-risk assessment. Journal of Biopharmaceutical Statistics 33:4, pages 452-465.
Read now
Read now
Jeff P. Sharman, Paulo Miranda, Jack Roos, Ugochinyere Emeribe, Ling Cai, Bengt Liljas & Priyanka Gaitonde. (2023) Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia. Leukemia & Lymphoma 64:7, pages 1243-1252.
Read now
Read now
Caitlyn T. Solem, Youngmin Kwon, Ruchit M. Shah, Abdalla Aly & Marc F. Botteman. (2018) Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology. Expert Review of Pharmacoeconomics & Outcomes Research 18:3, pages 245-253.
Read now
Read now
Jianmin Wang, Guy Hechmati, Jun Dong, Gregory A. Maglinte, Beth Barber & Jean-Yves Douillard. (2016) Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer. Current Medical Research and Opinion 32:3, pages 459-465.
Read now
Read now
Jiantian Wang & Yingfu Li. (2005) A note on non-identifiability of mark survival function. Journal of Nonparametric Statistics 17:8, pages 989-994.
Read now
Read now
Mahmoud Almanassra, Jiantian Wang & S. Jeyaratnam. (2005) Monotonic Estimators for the Survival Function of Quality Adjusted Lifetime. Communications in Statistics - Theory and Methods 34:5, pages 1217-1231.
Read now
Read now
Yijian Huang. (2000) Two-Sample Multistate Accelerated Sojourn Times Model. Journal of the American Statistical Association 95:450, pages 619-627.
Read now
Read now
Marco Bonetti, BernardF. Cole & RichardD. Gelber. (1999) A Method-of-Moments Estimation Procedure for Categorical Quality-of-Life Data with Nonignorable Missingness. Journal of the American Statistical Association 94:448, pages 1025-1034.
Read now
Read now
Articles from other publishers (22)
Etienne Lengliné, Joachim Baba, Paul de Boissieu, Alexandre Beaufils, Alice Desbiolles, Thierno Diatta, Pierre Cochat & Sylvie Chevret. (2024) Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS). European Journal of Cancer 204, pages 114047.
Crossref
Crossref
Erica E. M. Moodie & Denis Talbot. (2023) On “Reflections on the concept of optimality of single decision point treatment regimes”. Biometrical Journal 65:8.
Crossref
Crossref
Larry Dong, Erica E. M. Moodie, Laura Villain & Rodolphe Thiébaut. (2023) Evaluating the use of generalized dynamic weighted ordinary least squares for individualized HIV treatment strategies. The Annals of Applied Statistics 17:3.
Crossref
Crossref
Alexandra Bühler, Richard J. Cook & Jerald F. Lawless. (2023) Multistate models as a framework for estimand specification in clinical trials of complex processes. Statistics in Medicine 42:9, pages 1368-1397.
Crossref
Crossref
Joshua F. Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Heather Romero, Robert J. Fram, Douglas V. Faller, Mehul Dalal, Lionel Ades & Mikkael A. Sekeres. (2022) Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes. Haematologica 108:4, pages 1196-1199.
Crossref
Crossref
Andrea Antonuzzo, Carla Ida Ripamonti, Fausto Roila, Andrea Sbrana, Luca Galli, Guido Miccinesi, Enrico Sammarco, Alfredo Berruti, Deborah Coletta, Laura Velutti, Alessandra Fabi, Domenico Cristiano Corsi, Gabriella Mariani, Patricia Di Pede, Gian Paolo Spinelli, Daniele Santini, Fable Zustovich, Marco Gunnellini, Maura Rossi, Monica Giordano, Massimo Di Maio, Gianmauro Numico & Paolo Bossi. (2022) Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial. Frontiers in Oncology 12.
Crossref
Crossref
Shuai Chen & Jeffrey S. Hoch. (2022) Net‐benefit regression with censored cost‐effectiveness data from randomized or observational studies. Statistics in Medicine 41:20, pages 3958-3974.
Crossref
Crossref
C. H. Lee, Y. WanA. SmithR. XieR. J. Motzer. (2022) Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma. Cancer Urology 17:4, pages 54-64.
Crossref
Crossref
Mou'athA Hourani, NidalM Turab & QusaiY Shambour. (2017) The assessment of patient clinical outcome: A literature discussion. Annals of Tropical Medicine and Public Health 10:2, pages 321.
Crossref
Crossref
Diana Hughes, Ed Waddingham, Shahrul Mt‐Isa, Alesia Goginsky, Edmond Chan, Gerald F. Downey, Christine E. Hallgreen, Kimberley S. Hockley, Juhaeri Juhaeri, Alfons Lieftucht, Marilyn A. Metcalf, Rebecca A. Noel, Lawrence D. Phillips, Deborah Ashby & Alain Micaleff. (2016) Recommendations for benefit–risk assessment methodologies and visual representations. Pharmacoepidemiology and Drug Safety 25:3, pages 251-262.
Crossref
Crossref
Alberto Alvarez‐Iglesias, John Newell, Carl Scarrott & John Hinde. (2015) Summarising censored survival data using the mean residual life function. Statistics in Medicine 34:11, pages 1965-1976.
Crossref
Crossref
Wendy R. Tate & Grant H. Skrepnek. (2014) Quality‐adjusted time without symptoms or toxicity (Q‐TWiST): patient‐reported outcome or mathematical model? A systematic review in cancer. Psycho-Oncology 24:3, pages 253-261.
Crossref
Crossref
Shahrul Mt‐Isa, Christine E. Hallgreen, Nan Wang, Torbjörn Callréus, Georgy Genov, Ian Hirsch, Stephen F. Hobbiger, Kimberley S. Hockley, Davide Luciani, Lawrence D. Phillips, George Quartey, Sinan B. Sarac, Isabelle Stoeckert, Ioanna Tzoulaki, Alain Micaleff & Deborah Ashby. (2014) Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiology and Drug Safety 23:7, pages 667-678.
Crossref
Crossref
Caroline Whately‐Smith, Claire Watkins, Helen Mann, Chrissie Fletcher & Pierre Ducournau. (2014) Utility values in health technology assessments: a statistician's perspective. Pharmaceutical Statistics 13:3, pages 184-195.
Crossref
Crossref
J Wang, Z Zhao, B Barber, B Sherrill, M Peeters & J Wiezorek. (2011) A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. British Journal of Cancer 104:12, pages 1848-1853.
Crossref
Crossref
Arthur S. Zbrozek, Gary Hudes, Donna Levy, Andrew Strahs, Anna Berkenblit, Robert De Marinis & Shreekant Parasuraman. (2012) Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma. PharmacoEconomics 28:7, pages 577-584.
Crossref
Crossref
A.G. Pallis, C. Fortpied, U. Wedding, M.C. Van Nes, B. Penninckx, A. Ring, D. Lacombe, S. Monfardini, P. Scalliet & H. Wildiers. (2010) EORTC elderly task force position paper: Approach to the older cancer patient. European Journal of Cancer 46:9, pages 1502-1513.
Crossref
Crossref
Paolo Baldo, Maurizio Rupolo, Anna Compagnoni, Renzo Lazzarini, Alessandra Bearz, Renato Cannizzaro, Simon Spazzapan, Ivana Truccolo & Lorenzo Moja. (2010) Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Alan M. KellerRobert G. MennelVassilis A. GeorgouliasJean-Marc NabholtzAura ErazoAnna LluchCharles L. VogelManfred KaufmannGunther von MinckwitzI. Craig HendersonLillian MellarsLeila AllandCraig Tendler. (2004) Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer. Journal of Clinical Oncology 22:19, pages 3893-3901.
Crossref
Crossref
Alan N. GordonJohn T. FleagleDavid GuthrieDavid E. ParkinMartin E. GoreAngel J. Lacave. (2001) Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan. Journal of Clinical Oncology 19:14, pages 3312-3322.
Crossref
Crossref
Dave P. Miller, David J. Pasta, Susan D. Mathias, Hilary H. Colwell & James M. Henning. (2000) Quality-Days Incrementally Gained: A New Approach for Short-Term Evaluations Based on the Extended Q-TWiST Method Illustrated in a Clinical Study of Reflux Disease Patients. Drug Information Journal 34:2, pages 469-481.
Crossref
Crossref
S. K. ParsonsS. GelberB. F. ColeY. RavindranathA. OgdenA. M. YeagerM. ChangJ. ShusterH. J. WeinsteinR. D. Gelber. (1999) Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821. Journal of Clinical Oncology 17:7, pages 2144-2144.
Crossref
Crossref